Societe Generale’s BioMarin Pharmaceuticals BMRN Stock Holding History

Societe Generale’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$234K	Buy	+14,000	New	+$1.19M	﹤0.01%	2045

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Societe Generale's BMRN Position: Q2 2016 in Review

Societe Generale opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2016: 32,372 shares worth $2.52M. The stake represents 0.02% of the portfolio and ranks #717 among its holdings.

391 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

Societe Generale held 32,372 shares of BioMarin Pharmaceuticals worth $2.52M as of Q2 2016.
BioMarin Pharmaceuticals was a new Societe Generale position in Q2 2016.
BioMarin Pharmaceuticals made up 0.02% of Societe Generale's portfolio in Q2 2016, its #717 holding.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.